Each month, CREATION.co’s respiratory tracking update brings you the latest insights into the online UK healthcare professional (eHCP) conversation regarding respiratory disease.
Between 21 March and 20 April 2023, CREATION Pinpoint® tracked the online conversations of UK eHCPs discussing respiratory diseases. The average posts per day were slightly higher than the previous three months at 112 posts per day, totalling 3,354 posts. These posts were authored by 1,405 UK eHCPs. This month saw a slight increase in posts about pneumonia but a 67% decrease in posts about lung cancer compared to last month’s data.
Intensive care physician James Lynch posted the most frequently, sharing 81 posts. He had a particular interest in respiratory depression and also discussed pneumonia more than any other eHCP. 91% of his posts were in conversation with other eHCPs, who he educated and debated with.
eHCPs were most active on 21 March, when Asthma + Lung UK launched their #LungHealthLottery campaign. 44 UK eHCPs engaged with the campaign over the month, advocating for equality in access to respiratory healthcare. They shared posts from the charity alongside posts by influential figures such as local MPs.
📣 Today we launch our End The #LungHealthLottery campaign and need your help to urge the government to take lung conditions seriously. People in some areas of the UK are more likely to be hospitalised or die from a lung condition simply because of where they live. pic.twitter.com/OXqdhb7i9O
— Asthma + Lung UK (@asthmalunguk) March 21, 2023
On 5 April, Pfizer shared their positive phase 3 trial results of a bivalent prefusion F RSV vaccine in pregnancy. On the same day, Sanofi and AstraZeneca released trial results on nirsevimab for the prevention of RSV in infants. 44 eHCPs mentioned these ‘two fantastic RSV vaccine results.’
While 23% of these posts mentioned the two studies together, and 7% mentioned Sanofi’s on its own, 70% discussed Pfizer’s results. Of the 42 posts that discussed Pfizer’s results, 30 spoke about them being ‘exciting,’ ‘brilliant,’ or using other positive language. A paediatrician suggested that this might be ‘the beginning of the end for RSV bronchiolitis in all settings.’
Lots of new data today for RSV immunisation:
1. Positive data for nirsevimab: 77% efficacy for preventing RSV hospitalisation at 5 months
2. Slightly more mixed picture for maternal immunisation, but still 69.4% efficacy at 6 months for protecting against severe RSV LRTI 1/2 https://t.co/e88ipv8jPK
— Thomas Christie Williams (@Williams_T_C) April 6, 2023
The Paediatric Respiratory Conference was held on 18 April, and this generated discussion among several eHCPs, 68% of whom mentioned asthma. eHCPs were particularly interested in Christina Pearce’s research into ICS (inhaled corticosteroids) in asthmatic children and young people. She highlighted the importance of communicating about ICS use to children as well as to their parents.
Bringing together a holistic identification of at risk CYP #asthma patients
Navigating the NHS can be challenging and so identifying a key worker for at risk patients is massively helpful
— Seb Gray (@SebJGray) April 18, 2023
Each month, we track the eHCP conversation relating to respiratory disease.
You can keep up to date with this and other pharmaceutical tracking updates, including COVID-19 developments, within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights.
If you would like to dig deeper into what we have seen this month then please do get in touch.
- This article analysed the Twitter conversations of HCPs in the UK discussing respiratory disease and related terms between 21 March and 20 April 2023 using CREATION Pinpoint®.
- Between 21 March and 20 April 2023, there were 3,354 UK eHCP mentions of respiratory disease and related terms, from 1,405 unique UK eHCP authors.
Click here to read the latest respiratory tracker